Biotech News

iRhythm Announces $100 Million Accelerated Share Repurchase Agreement

iRhythm (IRTC)iRhythmCompany update

iRhythm Holdings, Inc. (Nasdaq: IRTC), a leading digital health care company with a mission to create trusted solutions that detect, predict, and prevent disease, today announced that it has entered into an accelerated share repurchase (ASR) agreement with JPMorgan Chase Bank, National Association (JPMorgan) for $100 million of its common stock, as part of its previously announced $200 million share repurchase authorization.

Related news

iRhythm

Ambulatory Cardiac Monitoring iRhythm is a digital healthcare company focused on detecting and characterizing cardiac arrhythmias. It combines wearable biosensors, cloud-based analytics and proprietary algorithms to convert extended electrocardiographic recordings into clinically actionable reports. Zio Platform The Zio portfolio...

Recent company news

Stock data

Close
94.24 USD
Market cap
3.47B USD
Exchange
NASDAQ
Sector
MedTech
Location
United States